Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI.

CA Cancer J Clin. 2019 Jul 8. doi: 10.3322/caac.21572. [Epub ahead of print] Review.

2.

miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.

Kresoja-Rakic J, Szpechcinski A, Kirschner MB, Ronner M, Minatel B, Martinez VD, Lam WL, Weder W, Stahel R, Früh M, Cerciello F, Felley-Bosco E.

Noncoding RNA. 2019 Jun 17;5(2). pii: E41. doi: 10.3390/ncrna5020041.

3.

Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).

Wu L, Dell'Anno I, Lapidot M, Sekido Y, Chan ML, Kohno M, Serre-Beinier V, Felley-Bosco E, de Perrot M.

Lung Cancer. 2019 Jan;127:138-145. doi: 10.1016/j.lungcan.2018.11.034. Epub 2018 Nov 29. Review.

PMID:
30642542
4.

Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions.

Felley-Bosco E.

Int J Mol Sci. 2018 Nov 12;19(11). pii: E3560. doi: 10.3390/ijms19113560.

5.

Asbestos: Modern Insights for Toxicology in the Era of Engineered Nanomaterials.

Felley-Bosco E, MacFarlane M.

Chem Res Toxicol. 2018 Oct 15;31(10):994-1008. doi: 10.1021/acs.chemrestox.8b00146. Epub 2018 Sep 12.

PMID:
30156102
6.

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.

Tallón de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode B, Opitz I, Vrugt B, Weder W, Stolzmann P, Felley-Bosco E, Stahel RA, Tischler V, Britschgi C, Soldini D, van den Broek M, Curioni-Fontecedro A.

Clin Cancer Res. 2018 Dec 15;24(24):6345-6354. doi: 10.1158/1078-0432.CCR-18-1231. Epub 2018 Aug 28.

PMID:
30154226
7.

Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection.

Bachas C, Hodzic J, van der Mijn JC, Stoepker C, Verheul HMW, Wolthuis RMF, Felley-Bosco E, van Wieringen WN, van Beusechem VW, Brakenhoff RH, de Menezes RX.

BMC Bioinformatics. 2018 Aug 20;19(1):301. doi: 10.1186/s12859-018-2306-z.

8.

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells.

Kresoja-Rakic J, Felley-Bosco E.

J Vis Exp. 2018 Apr 25;(134). doi: 10.3791/57516.

PMID:
29757292
9.

Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.

Wu L, Blum W, Zhu CQ, Yun Z, Pecze L, Kohno M, Chan ML, Zhao Y, Felley-Bosco E, Schwaller B, de Perrot M.

BMC Cancer. 2018 Apr 27;18(1):471. doi: 10.1186/s12885-018-4354-1.

10.

Non-Coding Transcript Heterogeneity in Mesothelioma: Insights from Asbestos-Exposed Mice.

Felley-Bosco E, Rehrauer H.

Int J Mol Sci. 2018 Apr 11;19(4). pii: E1163. doi: 10.3390/ijms19041163.

11.

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.

Oehl K, Kresoja-Rakic J, Opitz I, Vrugt B, Weder W, Stahel R, Wild P, Felley-Bosco E.

Front Oncol. 2018 Feb 23;8:40. doi: 10.3389/fonc.2018.00040. eCollection 2018.

12.

How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations.

Rehrauer H, Wu L, Blum W, Pecze L, Henzi T, Serre-Beinier V, Aquino C, Vrugt B, de Perrot M, Schwaller B, Felley-Bosco E.

Oncogene. 2018 May;37(20):2645-2659. doi: 10.1038/s41388-018-0153-z. Epub 2018 Mar 6.

13.

The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma.

Schürch CM, Forster S, Brühl F, Yang SH, Felley-Bosco E, Hewer E.

Oncoimmunology. 2017 Sep 21;7(1):e1373235. doi: 10.1080/2162402X.2017.1373235. eCollection 2017.

14.

Erratum to: Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line.

Blum W, Pecze L, Felley-Bosco E, Worthmüller-Rodriguez J, Wu L, Vrugt B, de Perrot M, Schwaller B.

In Vitro Cell Dev Biol Anim. 2017 Oct;53(9):853. doi: 10.1007/s11626-017-0194-6. No abstract available.

PMID:
28840527
15.

Long Noncoding RNAs in Cancer and Therapeutic Potential.

Renganathan A, Felley-Bosco E.

Adv Exp Med Biol. 2017;1008:199-222. doi: 10.1007/978-981-10-5203-3_7. Review.

PMID:
28815541
16.

Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.

Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, Schwaller B, Weder W, Stahel RA, Felley-Bosco E.

Front Genet. 2017 May 29;8:70. doi: 10.3389/fgene.2017.00070. eCollection 2017.

17.

A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.

Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, Felley-Bosco E.

J Thorac Oncol. 2017 Aug;12(8):1309-1319. doi: 10.1016/j.jtho.2017.03.023. Epub 2017 Apr 4.

18.

Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells.

Blum W, Pecze L, Felley-Bosco E, Wu L, de Perrot M, Schwaller B.

Stem Cell Reports. 2017 Apr 11;8(4):1005-1017. doi: 10.1016/j.stemcr.2017.02.005. Epub 2017 Mar 9.

19.

Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.

Meerang M, Bérard K, Friess M, Bitanihirwe BK, Soltermann A, Vrugt B, Felley-Bosco E, Bueno R, Richards WG, Seifert B, Stahel R, Weder W, Opitz I.

Mol Oncol. 2016 Oct;10(8):1255-65. doi: 10.1016/j.molonc.2016.06.005. Epub 2016 Jun 25.

20.

Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.

Kresoja-Rakic J, Kapaklikaya E, Ziltener G, Dalcher D, Santoro R, Christensen BC, Johnson KC, Schwaller B, Weder W, Stahel RA, Felley-Bosco E.

Oncotarget. 2016 Apr 19;7(16):21272-86. doi: 10.18632/oncotarget.7114.

Supplemental Content

Loading ...
Support Center